[11C]Choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging

Journal of Urology

Volumn 184, Issue 3, 2010, Pages 938-943

  Giovacchini, Giampiero ^a   Picchio, Maria ^b   Briganti, Alberto ^b   Cozzarini, Cesare ^b   Scattoni, Vincenzo ^b   Salonia, Andrea ^b   Landoni, Claudio ^b   Gianolli, Luigi ^b   Di Muzio, Nadia ^b   Rigatti, Patrizio ^b   Montorsi, Francesco ^b   Messa, Cristina ^a,c,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c CNR   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

Author keywords

choline; prostate; prostate specific antigen; prostatic neoplasms; tomography, emission computed

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; METHYL CARBON 11 CHOLINE; METHYL CARBON-11 CHOLINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; SCINTISCANNING; TREATMENT FAILURE; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CHOLINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE;

EID: 77956642500     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.04.084     Document Type: Article

References (30)

1. C.R. Pound, A.W. Partin, and M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591
2. D.T. Price, R.E. Coleman, and R.P. Liao Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer J Urol 168 2002 273
3. I.J. de Jong, J. Pruim, and P.H. Elsinga [11C]choline positron emission tomography for the evaluation after treatment of localized prostate cancer Eur Urol 44 2003 32
4. M. Picchio, C. Messa, and C. Landoni Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography J Urol 169 2003 1337
5. M. Heinisch, A. Dirisamer, and W. Loidl Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8 2006 43
6. L. Rinnab, N.M. Blumstein, and F.M. Mottaghy (11)C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer BJU Int 99 2007 1421
7. B.J. Krause, M. Souvatzoglou, and M. Tuncel The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 2008 18
8. S.N. Reske, N.M. Blumstein, and G. Glatting [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy Eur J Nucl Med Mol Imaging 35 2008 9
9. P. Castellucci, C. Fuccio, and C. Nanni Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy J Nucl Med 50 2009 1394
10. G. Giovacchini, M. Picchio, and E. Coradeschi Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy Eur J Nucl Med Mol Imaging 37 2010 301
11. V. Scattoni, M. Picchio, and N. Suardi Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy Eur Urol 52 2007 423
12. N. Oyama, D.E. Ponde, and C. Dence Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation J Nucl Med 45 2004 519
13. H.I. Scher, M. Eisenberger, and A.V. D'Amico Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 22 2004 537
14. T. Hara, N. Kosaka, and H. Kishi PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 1998 990
15. P.M. Arlen, F. Bianco, and W.L. Dahut Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time J Urol 179 2008 2181
16. R. Tiguert, E.L. Gheiler, and M.V. Tefilli Lymph node size does not correlate with the presence of prostate cancer metastasis Urology 53 1999 367
17. M.L. Cher, F.J. Bianco Jr, and J.S. Lam Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy J Urol 160 1998 1387
18. A. Heidenreich, G. Aus, and M. Bolla EAU guidelines on prostate cancer Eur Urol 53 2008 68
19. A.W. Partin, J.D. Pearson, and P.K. Landis Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases Urology 43 1994 649
20. Z.A. Dotan, F.J. Bianco Jr, and F. Rabbani Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy J Clin Oncol 23 2005 1962
21. M.W. Kattan, T.M. Wheeler, and P.T. Scardino Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 17 1999 1499
22. A.K. Leventis, S.F. Shariat, and K.M. Slawin Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings Radiology 219 2001 432
23. M.S. Soloway, S.W. Hardeman, and D. Hickey Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan Cancer 61 1988 195
24. D.T. Schmid, H. John, and R. Zweifel Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 2005 623
25. H. Vees, F. Buchegger, and S. Albrecht (18)F-choline and/or (11)C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/ml) after radical prostatectomy BJU Int 99 2007 1415
26. D.B. Husarik, R. Miralbell, and M. Dubs Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 2008 253
27. K.A. Roehl, M. Han, and C.G. Ramos Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results J Urol 172 2004 910
28. D. Schilling, H.P. Schlemmer, and P.H. Wagner Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer BJU Int 102 2008 446
29. R. Schiavina, V. Scattoni, and P. Castellucci 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms Eur Urol 54 2008 392
30. M. Roscigno, C. Cozzarini, and V. Scattoni A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy Radiother Oncol 82 2007 30